379 related articles for article (PubMed ID: 18809098)
1. Erythropoietic agents and the elderly.
Agarwal N; Prchal JT
Semin Hematol; 2008 Oct; 45(4):267-75. PubMed ID: 18809098
[TBL] [Abstract][Full Text] [Related]
2. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
Macdougall IC
Curr Hematol Rep; 2005 Nov; 4(6):436-40. PubMed ID: 16232379
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in erythropoietic agents in renal anemia.
Macdougall IC
Semin Nephrol; 2006 Jul; 26(4):313-8. PubMed ID: 16949470
[TBL] [Abstract][Full Text] [Related]
4. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
Trkulja V
Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
[TBL] [Abstract][Full Text] [Related]
5. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
6. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
Tanaka T; Nangaku M
Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietins: a common mechanism of action.
Elliott S; Pham E; Macdougall IC
Exp Hematol; 2008 Dec; 36(12):1573-84. PubMed ID: 18922615
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease.
Gupta N; Wish JB
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):345-350. PubMed ID: 29746307
[TBL] [Abstract][Full Text] [Related]
9. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
10. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Biochim Biophys Acta; 2007 Sep; 1776(1):1-9. PubMed ID: 17683868
[TBL] [Abstract][Full Text] [Related]
11. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients.
Toida T; Sato Y; Shibata N; Kitamura K; Fujimoto S
Blood Purif; 2014; 38(3-4):174-9. PubMed ID: 25502179
[TBL] [Abstract][Full Text] [Related]
12. Novel erythropoiesis-stimulating agents: a new era in anemia management.
Macdougall IC
Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
[TBL] [Abstract][Full Text] [Related]
13. [Erythropoietin: receptor of stimulating agents of erythropoiesis].
Rieu P
Nephrol Ther; 2008 Oct; 4 Spec No 2():17-22. PubMed ID: 19000894
[No Abstract] [Full Text] [Related]
14. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
[TBL] [Abstract][Full Text] [Related]
16. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
Bieber E
J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
[TBL] [Abstract][Full Text] [Related]
18. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.
Deicher R; Hörl WH
Drugs; 2004; 64(5):499-509. PubMed ID: 14977387
[TBL] [Abstract][Full Text] [Related]
19. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
20. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
Mark TL; McKenzie RS; Fastenau J; Piech CT
Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
